| Name | Title | Contact Details |
|---|
Global Dosimetry Solutions, Inc. (GDS) is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aids Project New Haven is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Unisyn Medical Technologies is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The all-in-one digital solution for gut health and disease. We`re helping people feel better, while lowering their cost of care. At Vivante, we`re taking on digestive disease because an astonishing 70 million people in the US are affected—that`s twice the number with diabetes and more than many other chronic conditions combined. Unlike other chronic conditions, though, digestive diseases are often untreated or misdiagnosed...because of stigma. Over half of adults with digestive trouble admit they haven`t even consulted a provider about their symptoms. This is unfortunate because chronic digestive symptoms take a toll on home life, work performance, romance, and even simple social events. And digestive disease is expensive! For most companies, GI claims are the #2 healthcare expense, second only to cancer. Specialty drugs for inflammatory bowel disease can run $70k per year for just ONE employee. Now is the time for employers and health plans to address digestive health, while at the same time providing REAL help to the millions who are struggling and don`t know where to turn. Our all-in-one digital program, GIThrive®, empowers people—through brilliant technology and advanced science—to spend less time worrying about their digestive symptoms and more time living life. A wonderful byproduct of the GIThrive success is reduced medical and Rx drug spending for employers, health plans and individuals.
Halberd Corporation has acquired exclusive licenses to two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and Cerebrospinal Fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other virus`. The issued patents` extracorporeal technology is applicable to a significant number of the most debilitating and often fatal illnesses affecting mankind: PTSD, CTE (Chronic Traumatic Encephalopathy) and Cancer, among others. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. In addition, we have initiated the development of potential patient trial application lists. Our management team has extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment.